282 related articles for article (PubMed ID: 15118275)
21. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas.
Plöckinger U; Albrecht S; Mawrin C; Saeger W; Buchfelder M; Petersenn S; Schulz S
J Clin Endocrinol Metab; 2008 Apr; 93(4):1203-10. PubMed ID: 18198230
[TBL] [Abstract][Full Text] [Related]
22. The growth hormone (GH)-axis of GH receptor/binding protein gene-disrupted and metallothionein-human GH-releasing hormone transgenic mice: hypothalamic neuropeptide and pituitary receptor expression in the absence and presence of GH feedback.
Peng XD; Park S; Gadelha MR; Coschigano KT; Kopchick JJ; Frohman LA; Kineman RD
Endocrinology; 2001 Mar; 142(3):1117-23. PubMed ID: 11181526
[TBL] [Abstract][Full Text] [Related]
23. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
24. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
25. Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro.
Gruszka A; Culler MD; Melmed S
Mol Cell Endocrinol; 2012 Oct; 362(1-2):104-9. PubMed ID: 22705877
[TBL] [Abstract][Full Text] [Related]
26. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
[TBL] [Abstract][Full Text] [Related]
27. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
[TBL] [Abstract][Full Text] [Related]
28. Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures.
Djordjijevic D; Zhang J; Priam M; Viollet C; Gourdji D; Kordon C; Epelbaum J
Endocrinology; 1998 May; 139(5):2272-7. PubMed ID: 9564833
[TBL] [Abstract][Full Text] [Related]
29. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment.
Ballarè E; Persani L; Lania AG; Filopanti M; Giammona E; Corbetta S; Mantovani S; Arosio M; Beck-Peccoz P; Faglia G; Spada A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3809-14. PubMed ID: 11502816
[TBL] [Abstract][Full Text] [Related]
30. Ghrelin receptor (GHS-R1a) and its constitutive activity in somatotroph adenomas: a new co-targeting therapy using GHS-R1a inverse agonists and somatostatin analogs.
Mear Y; Blanchard MP; Defilles C; Brue T; Figarella-Branger D; Graillon T; Manavela M; Barlier A; Enjalbert A; Thirion S
J Clin Endocrinol Metab; 2014 Dec; 99(12):E2463-71. PubMed ID: 25272306
[TBL] [Abstract][Full Text] [Related]
31. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.
Zatelli MC; Piccin D; Tagliati F; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Culler MD; degli Uberti EC
J Clin Endocrinol Metab; 2003 Jun; 88(6):2797-802. PubMed ID: 12788890
[TBL] [Abstract][Full Text] [Related]
32. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
[TBL] [Abstract][Full Text] [Related]
33. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
Schaer JC; Waser B; Mengod G; Reubi JC
Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin receptor subtype gene expression in pituitary adenomas.
Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
[TBL] [Abstract][Full Text] [Related]
35. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
36. Somatostatin receptors in pituitary function, diagnosis and therapy.
Hofland LJ; Lamberts SW
Front Horm Res; 2004; 32():235-52. PubMed ID: 15281350
[TBL] [Abstract][Full Text] [Related]
37. Treatment of thyrotropin-secreting pituitary adenomas with octreotide.
Shimatsu A; Murabe H; Kamoi K; Suzuki Y; Nakao K
Endocr J; 1999 Feb; 46(1):113-23. PubMed ID: 10426575
[TBL] [Abstract][Full Text] [Related]
38. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
[TBL] [Abstract][Full Text] [Related]
39. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
Jaquet P; Saveanu A; Gunz G; Fina F; Zamora AJ; Grino M; Culler MD; Moreau JP; Enjalbert A; Ouafik LH
J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
[TBL] [Abstract][Full Text] [Related]
40. Cytoplasmic expression of SSTR2 and 5 by immunohistochemistry and by RT/PCR is not associated with the pharmacological response to octreotide.
Gonzalez B; Vargas G; Ramirez C; Asa S; Cheng S; Sandoval C; Mercado M
Endocrinol Nutr; 2014 Dec; 61(10):523-30. PubMed ID: 25008035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
